Squamous cell carcinoma (SCC) of the bladder is a distinct and rarer form, accounting for approximately 2% to 5% of all bladder cancers in the U.S. It develops in the flat, thin squamous cells that ...

Personal cancer journey emphasizes the emotional and physical challenges faced by patients during diagnosis and treatment. Patient advocacy is crucial in navigating the healthcare system and making ...

This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

Analysis of gene mutations, TMB, and PD-L1 in relation to ICI response in HNSCC. Retlirafusp alfa-a bifunctional anti-PD-L1/TGF-βRII agent plus nab-paclitaxel and carboplatin in pre-treated ...

The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Extreme heat and plenty of sunshine is a given for Atlanta, especially this summer. In June, there were nearly 285 hours of sunshine, and we’re on track for more rays this month, according to U.S.

C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.